These findings illustrate that the ChP blood–CSF barrier permeability was compromised after ischemic stroke, and pharmacological blockade of SPAK–NKCC1 complex protected the ChP blood–CSF barrier integrity. The gene discussed is STK39; the disease is ischemic stroke.